Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care

Ocular Toxicities, Antibody-Drug Conjugates, and Multiple Myeloma: The Importance of Coordinating Ophthalmologic and Oncologic Care is organized by RedMedEd.

Release Date: 8/10/2021
Expiration Date:  8/10/2022

Overview:
The past two decades have seen the development of numerous new targeted therapies for multiple myeloma (MM). Included among these are antibody–drug conjugates (ADCs), which have shown significant promise in improving patient prognoses but are associated with unique adverse events (AEs). In particular, ADCs containing monomethyl auristatin F (MMAF) have been linked to increased incidence of corneal epithelial changes. With the FDA’s 2020 approval of belantamab mafodotin (the first ADC indicated for MM treatment)—and its accompanying risk evaluation and mitigation strategy (REMS)—the issues of managing potential ocular toxicity and conducting routine ophthalmologic monitoring throughout the course of treatment become paramount.

This monograph has been developed to provide ophthalmologists and optometrists involved in the care of MM patients receiving belantamab mafodotin guidance on the recommended management strategies for immunotherapy-associated ocular AEs.

Learning Objectives:
Upon completion of this activity, participants should be better able to:
• Describe the symptoms and severity of corneal microcyst-like epithelial changes occurring as a result of ADC use in patients with MM
• Provide the recommended ophthalmologic monitoring of patients on ADCs to prevent treatment complications